health pharma news today obesity drugs glp-1 The next phase of the drug race Skyrocketing Cost of Obesity Drugs
Description
8e), as manifested by increased PWL in the Hargreaves test
We included patients who had been treated with an SGLT2i or GLP-1 RA for at least 6 months and analysed the efficacy, safety and cardio-renal outcomes 5 years after initiation of therapy
GLP-1 therapy should complement, not replace, appropriate orthopedic or rheumatologic treatment for joint conditions
doi: 10.1056/NEJMoa1912388
Rest of Africa 19.4
